Baseline characteristics
Characteristic . | Stable group, n = 2504 . | Comparator group, n = 3569 . | P . |
---|---|---|---|
Mean age,* y (SD) | 72.3 (10.9) | 68.8 (13.1) | < .001 |
Age older than 70 y, % | 63.0 | 51.5 | < .001 |
Male, % | 52.0 | 51.5 | .688 |
INR target, % | |||
2.0 | 3.9 | 3.3 | .167 |
2.5 | 87.0 | 79.7 | < .001 |
3.0 or more | 9.1 | 17.0 | < .001 |
Primary indication for anticoagulation therapy, % | |||
Atrial fibrillation | 49.9 | 43.4 | < .001 |
Venous thromboembolism | 25.6 | 25.8 | .856 |
Heart valve disorder | 8.0 | 12.7 | < .001 |
Other | 16.5 | 18.1 | .107 |
Risk factors, % | |||
Diabetes mellitus† | 1.6 | 3.5 | < .001 |
Hypertension† | 18.2 | 20.2 | .046 |
Heart failure† | 5.9 | 8.7 | < .001 |
Prior venous thrombosis† | 2.5 | 3.7 | .012 |
Prior hemorrhage† | 1.2 | 2.0 | .021 |
Prior stroke† | 0.0 | 0.1 | .273 |
Cancer† | 0.2 | 0.6 | .060 |
Estrogen therapy‡ | 7.8 | 10.7 | < .001 |
Mean chronic disease score (SD) | 6.5 (2.6) | 6.7 (2.7) | < .001 |
Median duration of warfarin therapy, d§ (IQR) | 1166 (554, 2051) | 755 (725, 1753) | .743 |
Characteristic . | Stable group, n = 2504 . | Comparator group, n = 3569 . | P . |
---|---|---|---|
Mean age,* y (SD) | 72.3 (10.9) | 68.8 (13.1) | < .001 |
Age older than 70 y, % | 63.0 | 51.5 | < .001 |
Male, % | 52.0 | 51.5 | .688 |
INR target, % | |||
2.0 | 3.9 | 3.3 | .167 |
2.5 | 87.0 | 79.7 | < .001 |
3.0 or more | 9.1 | 17.0 | < .001 |
Primary indication for anticoagulation therapy, % | |||
Atrial fibrillation | 49.9 | 43.4 | < .001 |
Venous thromboembolism | 25.6 | 25.8 | .856 |
Heart valve disorder | 8.0 | 12.7 | < .001 |
Other | 16.5 | 18.1 | .107 |
Risk factors, % | |||
Diabetes mellitus† | 1.6 | 3.5 | < .001 |
Hypertension† | 18.2 | 20.2 | .046 |
Heart failure† | 5.9 | 8.7 | < .001 |
Prior venous thrombosis† | 2.5 | 3.7 | .012 |
Prior hemorrhage† | 1.2 | 2.0 | .021 |
Prior stroke† | 0.0 | 0.1 | .273 |
Cancer† | 0.2 | 0.6 | .060 |
Estrogen therapy‡ | 7.8 | 10.7 | < .001 |
Mean chronic disease score (SD) | 6.5 (2.6) | 6.7 (2.7) | < .001 |
Median duration of warfarin therapy, d§ (IQR) | 1166 (554, 2051) | 755 (725, 1753) | .743 |